Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of “Hold” by Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.39.

A number of analysts have recently commented on RVNC shares. StockNews.com began coverage on Revance Therapeutics in a research note on Saturday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Finally, Mizuho lowered their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.65 on Thursday. The company has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56. The business’s fifty day moving average is $3.42 and its 200 day moving average is $4.60.

Institutional Investors Weigh In On Revance Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RVNC. Natixis bought a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $31,000. Two Sigma Securities LLC bought a new stake in Revance Therapeutics during the 4th quarter worth approximately $35,000. Alpine Global Management LLC bought a new position in shares of Revance Therapeutics in the fourth quarter worth $37,000. FORA Capital LLC bought a new stake in Revance Therapeutics during the third quarter valued at $54,000. Finally, RPO LLC purchased a new position in Revance Therapeutics during the fourth quarter worth about $55,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.